Estrogen receptor beta as target for colorectal cancer prevention

Cancer Letters

Volumn 372, Issue 1, 2016, Pages 48-56

  Williams, Cecilia ^a,b,c   DiLeo, Alfredo ^d   Niv, Yaron ^e   Gustafsson, Jan Åke ^a,c  

^a University of Houston   (United States)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF BARI   (Italy)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Colorectal cancer; Estrogen; Estrogen receptor beta; Gene expression; Phytoestrogens; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; ESTROGEN; ESTROGEN RECEPTOR BETA; PHYTOESTROGEN; PROTEIN P53; RALOXIFENE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ANTAGONIST;

APOPTOSIS; CANCER INCIDENCE; CANCER MODEL; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CARDIOVASCULAR DISEASE; COLON MUCOSA; COLONOSCOPY; COLORECTAL CANCER; DNA REPAIR; DRUG MEGADOSE; DRUG SAFETY; ESR2 GENE; ESTROGEN THERAPY; FAMILIAL COLON POLYPOSIS; GENE DELETION; GENE REPRESSION; GENETIC ASSOCIATION; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RISK REDUCTION; SEX DIFFERENCE; SHORT SURVEY; SIGMOIDOSCOPY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; ADENOMATOUS POLYPS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; COLON; COLONIC POLYPS; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; RISK FACTOR;

ADENOCARCINOMA; ADENOMATOUS POLYPS; ANIMALS; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLONIC POLYPS; COLORECTAL NEOPLASMS; ESTROGEN RECEPTOR ANTAGONISTS; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84958213395     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.12.009     Document Type: Review

References (104)

1. American Cancer Society Cancer Facts and Figures 2015 American Cancer Society. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
2. Muto T., Bussey H.J., Morson B.C. The evolution of cancer of the colon and rectum. Cancer 1975, 26:2251-2270.
3. Michal S., Li L., Chen Z. Lifestyle and dietary risk factors for colorectal hyperplastic and adenomatous polyps. Cancer Epidemiol. Biomarkers Prev 2012, 21:563.
4. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening v2.2011 http://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf.
5. Niv Y., Hazazi R., Levi Z., Fraser G. Screening colonoscopy for colorectal cancer in asymptomatic people: a meta-analysis. Dig. Dis. Sci 2008, 53:3049-3054.
6. Cooper K., Squires H., Carroll C., Papaioannou D., Booth A., Logan R.F., et al. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol. Assess 2010, 14:1-206.
7. Rothwell P.M., Wilson M., Elwin C.E., Norrving B., Algra A., Warlow C.P., et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
8. Takayama T., Goji T., Taniguchi T., Inoue A. Chemoprevention of colorectal cancer-experimental and clinical aspects. J. Med. Invest 2009, 56:1-5.
9. Ford A.C., Brandt L.J., Young C., Chey W.D., Foxx-Orenstein A.E., Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol 2009, 104:1831-1843.
10. McCashland T.M., Brand R., Lyden E., de Garmo P. Gender differences in colorectal polyps and tumors. Am. J. Gastroenterol 2001, 96:882-886.
11. Chlebowski R.T., Wactawski-Wende J., Ritenbaugh C., Hubbell F.A., Ascensao J., Rodabough R.J., et al. Women's Health Initiative Investigators, Estrogen plus progestin and colorectal cancer in postmenopausal women. N. Engl. J. Med 2004, 350:991-1004.
12. Hendifar A., Yang D., Lenz F., Lurje G., Pohl A., Lenz C., et al. Gender disparities in metastatic colorectal cancer survival. Clin. Cancer Res 2009, 15:6391-6397.
13. Söderlund S., Granath F., Broström O., Karlén P., Löfberg R., Ekbom A., et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010, 138:1697-1703.
14. Fernandez E., La Vecchia C., Balducci A., Chatenoud L., Franceschi S., Negri E. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br. J. Cancer 2001, 84:722-727.
15. Long M.D., Martin C.F., Galanko J.A., Sandler R.S. Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: a population-based case-control study. Am. J. Gastroenterol 2010, 105:1843-1850.
16. Foster P.A. Oestrogen and colorectal cancer: mechanisms and controversies. Int. J. Colorectal Dis 2013, 28:737-749.
17. Prentice R.L., Pettinger M., Beresford S.A., Wactawski-Wende J., Hubbell F.A., Stefanick M.L., et al. Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol. Biomarkers Prev 2009, 18:1531-1537.
18. Lin K.J., Cheung W.Y., Lai J.Y., Giovannucci E.L. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int. J. Cancer 2012, 130:419-430.
19. Newcomb P.A., Zheng Y., Chia V.M., Morimoto L.M., Doria-Rose V.P., Templeton A., et al. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 2007, 67:7534-7539.
20. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
21. Yan L., Spitznagel E.L., Bosland M.C. Soy consumption and colorectal cancer risk in humans: a meta-analysis. Cancer Epidemiol. Biomarkers Prev 2010, 19:148.
22. Xu X., Duncan A.M., Wangen K.E., Kurzer M.S. Soy consumption alters endogenous estrogen metabolism in postmenopausal women. Cancer Epidemiol. Biomarkers Prev 2000, 9:781-786.
23. Walter P., Green S., Greene G., Krust A., Bornert J.M., Jeltsch J.M., et al. Cloning of the human estrogen receptor cDNA. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:7889-7893.
24. Kuiper G.G.J.M., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.-Å. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. PNAS 1996, 93:5925-5930.
25. Ascenzi P., Bocedi A., Marino M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med 2006, 27:299-402.
26. Pettersson K., Delaunay F., Gustafsson J.Å. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000, 19:4970-4978.
27. Hall J.M., McDonnell D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999, 140:5566-5578.
28. Chang E.C., Frasor J., Komm B., Katzenellenbogen B.S. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 2006, 147:4831-4842.
29. Williams C., Edvardsson K., Lewandowski S.A., Strom A., Gustafsson J.-Å. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 2008, 27:1019-1032.
30. Jonsson P., Katchy A., Williams C. Support of a bi-faceted role of ERβ in ERα-positive breast cancer cells. Endocr. Relat. Cancer 2014, 21:143-160.
31. Ray A., Prefontaine K.E., Ray P. Down-modulation of interleukin-gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J. Biol. Chem 1994, 269:12940-12946.
32. Galien R., Garcia T. Estrogen receptor impairs interleukin-expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 1997, 25:2424-2429.
33. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J.Å., Kushner P.J., et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508-1510.
34. Porter W., Saville B., Hoivik D., Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol 1997, 11:1569-1580.
35. Frasor J., Weaver A., Pradhan M., Dai Y., Miller L.D., Lin C.Y., et al. Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 2009, 69:8918-8925.
36. Levin E.R. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol 2005, 19:1951-1959.
37. Konstantinopoulos P.A., Kominea A., Vandoros G., Sykiotis G.P., Andricopoulos P., Varakis I., et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur. J. Cancer 2003, 39:1251-1258.
38. Campbell-Thompson M., Lynch I.J., Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001, 61:632-640.
39. Jassam N., Bell S.M., Speirs V., Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncol. Rep 2005, 14:17-21.
40. Foley E.F., Jazaeri A.A., Shupnik M.A., Jazaeri O., Rice L.W. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000, 60:245-248.
41. Qiu Y., Waters C.E., Lewis A.E., Langman M.J., Eggo M.C. Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J. Endocrinol 2002, 174:369-377.
42. Xie L.Q., Yu J.P., Luo H.S. Expression of estrogen receptor beta in human colorectal cancer. World J. Gastroenterol 2004, 10:214-217.
43. Wong N.A., Malcomson R.D., Jodrell D.I., Groome N.P., Harrison D.J., Saunders P.T. ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J. Pathol 2005, 207:53-60.
44. Castiglione F., Taddei A., Rossi Degl'Innocenti D., Buccoliero A.M., Bechi P., Garbini F., et al. Expression of estrogen receptor beta in colon cancer progression. Diagn. Mol. Pathol 2008, 17:231-236.
45. Edvardsson K., Vu T.H., Kalasekar S.M., Ponten F., Gustafsson J.-Å., Williams C. Estrogen receptor beta expression induces changes in the microRNA pool in human colon cancer cells. Carcinogenesis 2013, 34:1431-1441.
46. Barone M., Scavo M.P., Papagni S., Piscitelli D., Guido R., Di Lena M., et al. ERbeta expression in normal, adenomatous and carcinomatous tissues of patients with familial adenomatous polyposis. Scand. J. Gastroenterol 2010, 45:1320-1328.
47. Di Leo A., Barone M., Maiorano E., Tanzi S., Piscitelli D., Marangi S., et al. ER-beta expression in large bowel adenomas: implications in colon carcinogenesis. Dig. Liver Dis 2008, 40:260-266.
48. Nussler N.C., Reinbacher K., Shanny N., Schirmeier A., Glanemann M., Neuhaus P., et al. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gend. Med 2008, 5:209-217.
49. Fang Y.J., Lu Z.H., Wang F., Wu X.J., Li L.R., Zhang L.Y., et al. Prognostic impact of ERbeta and MMP7 expression on overall survival in colon cancer. Tumour Biol 2010, 31:651-658.
50. Rudolph A., Toth C., Hoffmeister M., Roth W., Herpel E., Jansen L., et al. Expression of oestrogen receptor beta and prognosis of colorectal cancer. Br. J. Cancer 2012, 107:831-839.
51. Fang Y.J., Zhang L., Wu X.J., Lu Z.H., Li J.B., Ou Q.J., et al. Impact of ERβ and CD44 expression on the prognosis of patients with stage II colon cancer. Tumour Biol 2012, 33:1907-1914.
52. Rudolph A., Toth C., Hoffmeister M., Roth W., Herpel E., Schirmacher P., et al. Colorectal cancer risk associated with hormone use varies by expression of estrogen receptor-β. Cancer Res 2013, 73:3306-3315.
53. Levine A.J., Ihenacho U., Lee W., Figueiredo J.C., Vandenberg D.J., Edlund C.K., et al. Genetic variation in insulin pathway genes and distal colorectal adenoma risk. Int. J. Colorectal Dis 2012, 27:1587-1595.
54. Honma N., Yamamoto K., Ohnaka K., Morita M., Toyomura K., Kono S., et al. Estrogen receptor-β gene polymorphism and colorectal cancer risk: effect modified by body mass index and isoflavone intake. Int. J. Cancer 2013, 132:951-958.
55. Passarelli M.N., Phipps A.I., Potter J.D., Makar K.W., Coghill A.E., Wernli K.J., et al. Common single-nucleotide polymorphisms in the estrogen receptor β promoter are associated with colorectal cancer survival in postmenopausal women. Cancer Res 2013, 73:767-775.
56. Weige C.C., Allred K.F., Allred C.D. Estradiol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon. Cancer Res 2009, 69:9118-9124.
57. Cho N.L., Javid S.H., Carothers A.M., Redston M., Bertagnolli M.M. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 2007, 67:2366-2372.
58. Weyant M.J., Carothers A.M., Mahmoud N.N., Bradlow H.L., Remotti H., Bilinski R.T., et al. Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res 2001, 61:2547-2551.
59. Giroux V., Lemay F., Bernatchez G., Robitaille Y., Carrier J.C. Estrogen receptor β deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int. J. Cancer 2008, 123:303-311.
60. Cleveland A.G., Oikarinen S.I., Bynote K.K., Marttinen M., Rafter J.J., Gustafsson J.A., et al. Disruption of estrogen receptor signaling enhances intestinal neoplasia in Apc(Min/+) mice. Carcinogenesis 2009, 30:1581-1590.
61. Saleiro D., Murillo G., Benya R.V., Bissonnette M., Hart J., Mehta R.G. Estrogen receptor-β protects against colitis-associated neoplasia in mice. Int. J. Cancer 2012, 131:2553-2561.
62. Heijmans J., Wielenga M.C., Rosekrans S.L., van Lidth de Jeude J.F., Roelofs J., Groothuis P., et al. Oestrogens promote tumorigenesis in a mouse model for colitis-associated cancer. Gut 2014, 63:310-316.
63. Armstrong C.M., Billimek A.R., Allred K.F., Sturino J.M., Weeks B.R., Allred C.D. A novel shift in estrogen receptor expression occurs as estradiol suppresses inflammation-associated colon tumor formation. Endocr. Relat. Cancer 2013, 20:515-525.
64. Giroux V., Bernatchez G., Carrier J.C. Chemopreventive effect of ERβ-selective agonist on intestinal tumorigenesis in ApcMin/+ Mice. Mol. Carcinog 2011, 50:359-369.
65. Janakiram N.B., Mohammed A., Zhang Y., Brewer M., Bryant T., Lightfoot S., et al. Chemopreventive efficacy of raloxifene, bexarotene, and their combination on the progression of chemically induced colon adenomas to adenocarcinomas in rats. Cancer Prev. Res. (Phila.) 2013, 6:1251-1261.
66. Tu Z., Ma Y., Tian J., Li H., Akers W., Achilefu S., et al. Estrogen receptor β potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells. J. Cancer Res. Clin. Oncol 2012, 138:1091-1103.
67. Chae Y.J., Kim D.H., Lee H.J., Sung K.W., Kwon O.J., Hahn S.J. Raloxifene inhibits cloned Kv4.3 channels in an estrogen receptor-independent manner. Pflugers Arch 2015, 467(8):1663-1676.
68. Janakiram N.B., Mohammed A., Brewer M., Bryant T., Biddick L., Lightfoot S., et al. Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells. Cancer Prev. Res. (Phila.) 2014, 7:300-309.
69. Javid S.H., Moran A.E., Carothers A.M., Redston M., Bertagnolli M.M. Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. Carcinogenesis 2005, 26:587-595.
70. Guo J.Y., Li X., Browning J.D., Rottinghaus G.E., Lubahn D.B., Constantinou A., et al. Dietary soy isoflavones and estrone protect ovariectomized ERalphaKO and wild-type mice from carcinogen-induced colon cancer. J. Nutr 2004, 134:179-182.
71. Wada-Hiraike O., Imamov O., Hiraike H., Hultenby K., Schwend T., Omoto Y., et al. Role of estrogen receptor beta in colonic epithelium. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2959-2964.
72. Menon R., Watson S.E., Thomas L.N., Allred C.D., Dabney A., Azcarate-Peril M.A., et al. Diet complexity and estrogen receptor β status affect the composition of the murine intestinal microbiota. Appl. Environ. Microbiol 2013, 79:5763-5773.
73. Barone M., Tanzi S., Lofano K., Scavo M.P., Pricci M., Demarinis L., et al. Dietary-induced ERbeta upregulation counteracts intestinal neoplasia development in intact male ApcMin/+ mice. Carcinogenesis 2010, 31:269-274.
74. Rajamanickam S., Kaur M., Velmurugan B., Singh R.P., Agarwal R. Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway. Pharm. Res 2009, 26:2558-2567.
75. Rajamanickam S., Velmurugan B., Kaur M., Singh R.P., Agarwal R. Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res 2010, 70:2368-2378.
76. Hasson R.M., Briggs A., Carothers A.M., Davids J.S., Wang J., Javid S.H., et al. Estrogen receptor alpha or beta loss in the colon of Min/+ mice promotes crypt expansion and impairs TGFbeta and HNF3beta signaling. Carcinogenesis 2014, 35:96-102.
77. Weige C.C., Allred K.F., Armstrong C.M., Allred C.D. P53 mediates estradiol induced activation of apoptosis and DNA repair in non-malignant colonocytes. J. Steroid Biochem. Mol. Biol 2012, 128:113-120.
78. Velmurugan B., Singh R.P., Tyagi A., Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev. Res. (Phila.) 2008, 1:376-384.
79. Volate S.R., Davenport D.M., Muga S.J., Wargovich M.J. Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis 2005, 26:1450-1456.
80. Hartman J., Edvardsson K., Lindberg K., Zhao C., Williams C., Ström A., et al. Tumor repressive functions of estrogen receptor β in SW480 colon cancer cells. Cancer Res 2009, 69:6100-6106.
81. Singh R.P., Gu M., Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 2008, 68:2043-2050.
82. Principi M., De Tullio N., Scavo M.P., Piscitelli D., Marzullo A., Russo S., et al. Estrogen receptors expression in long-lasting ulcerative pancolitis with and without dysplasia: a preliminary report. Scand. J. Gastroenterol 2012, 47:1253-1254.
83. Principi M., Scavo M.P., Piscitelli D., Villanacci V., Lovero R., Losurdo G., et al. The sharp decline of beta estrogen receptors expression in long-lasting ulcerative-associated carcinoma. Scand. J. Gastroenterol 2015, 50:1002-1010.
84. Irrazábal T., Belcheva A., Girardin S.E., Martin A., Philpott D.J. The multifaceted role of the intestinal microbiota in colon cancer. Mol. Cell 2014, 54:309-320.
85. Yu C.-P., Ahuja R., Sayler G., Chu K.-H. Quantitative molecular assay for fingerprinting microbial communities of wastewater and estrogen-degrading consortia. Appl. Environ. Microbiol 2005, 71:1433-1444.
86. Martineti V., Picariello L., Tognarini I., Carbonell Sala S., Gozzini A., Azzari C., et al. ERb is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr. Relat. Cancer 2005, 12:455-469.
87. Tu Z., Ma Y., Akers W., Achilefu S., Gu Y. Therapeutic effect of the treatment for colorectal cancer with adenoviral vectors mediated estrogen receptor β gene therapy combined with thermotherapy. J. Cancer Res. Clin. Oncol 2014, 140:623-632.
88. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med 1988, 319:525-532.
89. Liu X., Lazenby A.J., Siegal G.P. Signal transduction cross-talk during colorectal tumorigenesis. Adv. Anat. Pathol 2006, 13:270-274.
90. Vogelstein B., Fearon E.R., Kern S.E., Hamilton S.R., Preisinger A.C., Nakamura Y., et al. Allelotype of colorectal carcinomas. Science 1989, 244:207-211.
91. Snover D.C. Update on the serrated pathway to colorectal carcinoma. Hum. Pathol 2011, 42:1-10.
92. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58:5248-5257.
93. Jin P., Lu X.J., Sheng J.Q., Fu L., Meng X.M., Wang X., et al. Estrogen stimulates the expression of mismatch repair gene hMLH1 in colonic epithelial cells. Cancer Prev. Res. (Phila.) 2010, 3:910-916.
94. Hsu H.H., Cheng S.F., Wu C.C., Chu C.H., Weng Y.J., Lin C.S., et al. Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin. J. Physiol 2006, 49:110-116.
95. Edvardsson K., Ström A., Jonsson P., Gustafsson J.-Å., Williams C. Estrogen receptor beta induces anti-inflammatory and anti-tumorigenic networks in colon cancer cells. Mol. Endocrinol 2011, 25:969-979.
96. Skog M., Bono P., Lundin M., Lundin J., Louhimo J., Linder N., et al. Expression and prognostic value of transcription factor PROX1 in colorectal cancer. Br. J. Cancer 2011, 105:1346-1351.
97. Petrova T.V., Nykanen A., Norrmen C., Ivanov K.I., Andersson L.C., Haglund C., et al. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell 2008, 13:407-419.
98. Nguyen-Vu T., Wang J., Mesmar F., Mukhopadhyay S., Saxena A., McCollum C.W., et al. ERβ decreases metastatic potential of colorectal cancer cells through the upregulation of miR-205 and its direct targeting of PROX1 Manuscript 2015.
99. Kennelly R., Kavanagh D.O., Hogan A.M., Winter D.C. Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 2008, 9:385-391.
100. El-Shitany N.A., Hegazy S., El-Desoky K. Evidences for antiosteoporotic and selective estrogen receptor modulator activity of silymarin compared with ethinylestradiol in ovariectomized rats. Phytomedicine 2010, 17:116-125.
101. Principi M., Di Leo A., Pricci M., Scavo M.P., Guido R., Tanzi S., et al. Phytoestrogens/insoluble fibers and colonic estrogen receptor β: randomized, double-blind, placebo-controlled study. World J. Gastroenterol 2013, 19:4325-4333.
102. Calabrese C., Pratico C., Calafiore A., Coscia M., Gentilini L., Poggioli G., et al. Eviendep(R) reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosis. World J. Gastroenterol 2013, 19:5671-5677.
103. Bringiotti R., Ierardi E., Lovero R., Losurdo G., Leo A.D., Principi M. Intestinal microbiota: the explosive mixture at the origin of inflammatory bowel disease?. World J. Gastrointest. Pathophysiol 2014, 5:550-559.
104. Deep G., Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010, 29:447-463.